Tempus AI, Inc. (NASDAQ:TEM) Given Consensus Rating of “Moderate Buy” by Brokerages

Tempus AI, Inc. (NASDAQ:TEMGet Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve research firms that are covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $61.18.

Several analysts have recently issued reports on TEM shares. William Blair reissued a “market perform” rating on shares of Tempus AI in a report on Tuesday, February 25th. Guggenheim reiterated a “buy” rating on shares of Tempus AI in a research note on Tuesday, February 25th. Loop Capital dropped their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Wolfe Research lowered shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Finally, TD Cowen restated a “buy” rating and set a $74.00 price objective (up from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th.

Get Our Latest Stock Report on TEM

Insider Activity

In other Tempus AI news, CEO Eric P. Lefkofsky sold 562,345 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $50.93, for a total value of $28,640,230.85. Following the completion of the transaction, the chief executive officer now directly owns 9,457,283 shares in the company, valued at approximately $481,659,423.19. This represents a 5.61 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrew Polovin sold 1,130 shares of Tempus AI stock in a transaction on Monday, December 16th. The stock was sold at an average price of $40.23, for a total transaction of $45,459.90. Following the transaction, the executive vice president now owns 244,955 shares in the company, valued at approximately $9,854,539.65. This trade represents a 0.46 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,755,906 shares of company stock worth $322,788,693.

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its stake in shares of Tempus AI by 13.2% in the fourth quarter. Wells Fargo & Company MN now owns 2,384 shares of the company’s stock valued at $80,000 after buying an additional 278 shares during the period. First Horizon Advisors Inc. acquired a new stake in Tempus AI during the 3rd quarter valued at approximately $30,000. Geode Capital Management LLC raised its holdings in Tempus AI by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after purchasing an additional 539 shares during the last quarter. Operose Advisors LLC acquired a new position in shares of Tempus AI in the 4th quarter worth approximately $25,000. Finally, Prestige Wealth Management Group LLC boosted its stake in shares of Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after purchasing an additional 965 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Stock Performance

Shares of NASDAQ:TEM opened at $47.17 on Friday. The business’s 50 day simple moving average is $55.33 and its 200 day simple moving average is $51.71. Tempus AI has a 1 year low of $22.89 and a 1 year high of $91.45. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

About Tempus AI

(Get Free Report

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Further Reading

Analyst Recommendations for Tempus AI (NASDAQ:TEM)

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.